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Gastrointestinal carcinomas frequently disseminate within the abdominal cavity to form secondary peritoneal metastases. Invasion of
the peritoneal mesothelium is fundamental to this process, yet the underlying invasive mechanisms remain unclear. Preliminary in vitro
work suggested that tumour cells can induce mesothelial apoptosis, representing a novel mechanism of peritoneal invasion. We
examined the role of tumour cell-induced mesothelial apoptosis and explored the role of the death ligand/receptor system, Fas
Ligand/Fas, as mediators of the apoptotic process. Cultured human mesothelial cells were used to establish in vitro co-culture models
with the SW480 colonic cancer cell line. Tumour-induced mesothelial apoptosis was confirmed by phase-contrast microscopy and
apoptotic detection assays. Human mesothelial cells and SW480 tumour cells constitutively expressed Fas and Fas Ligand mRNA and
protein as determined by RT–PCR and confocal fluorescent microscopy. Stimulation of human mesothelial cells with anti-Fas
monoclonal antibody or crosslinked soluble Fas Ligand-induced apoptosis, confirming the functional status of the Fas receptor.
Pretreatment of SW480 cells with a blocking recombinant anti-Fas Ligand monoclonal antibody significantly reduced mesothelial
apoptosis, indicating that tumour-induced mesothelial apoptosis may, in part, be mediated via a Fas-dependent mechanism. This
represents a novel mechanism of mesothelial invasion and offers several new targets for therapeutic intervention.
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Despite the peritoneum being a frequent site for the dissemination
of primary gastrointestinal cancers, little is known about the
mechanisms involved in peritoneal carcinomatosis. Of paramount
importance in the peritoneal metastatic cascade is the invasion by
tumour cells of the innermost layer of the peritoneum, the
mesothelium, a single layer of mesothelial cells. Only when this
protective barrier has been breached can tumour cells infiltrate
and proliferate within the submesothelial connective tissue matrix.
Several theories have been proposed, which attempt to explain
the mechanisms by which tumour cells invade the mesothelium.
Early animal studies suggested that invasion of the mesothelium
occurred by a process reminiscent of neutrophil extravasation,
with adherent tumour cells pushing cytoplasmic projections
between mesothelial intercellular junctions (Akedo et al, 1986).
Although the mechanisms of peritoneal neutrophil extravasation
have subsequently been well characterised, and the adhesion
molecules involved elucidated (Li et al, 1998), little evidence exists
to support a similar mechanism in peritoneal metastasis.
Other researchers have suggested that rather than ‘pushing’ their
way through the mesothelial monolayer, tumour cells induce
mesothelial retraction and dissagregation to gain access to the
submesothelial connective tissue. This phenomenon was believed
to result from soluble tumour-derived factors as it could be
reproduced by either tumour-conditioned media or exogenous
inflammatory cytokines (Yonemura et al, 1996, 1997).
More recently, it has been suggested that tumour adhesion,
rather than the presence of soluble factors, is the prerequisite for
mesothelial invasion. It is well documented that tumour cells
adhere rapidly to the mesothelium both in vivo and in vitro, and a
role for the cell adhesion molecule CD44 and the integrins b1, a2,
a3 and a5 in mesothelial invasion has been postulated (Kiyasu et al,
1981; Schlaeppi et al, 1997; Lessen et al, 1999; Strobel and
Cannistra, 1999). In these studies, tumour adhesion appeared to
precede dissagregation of the mesothelial monolayer, and could be
partially blocked by pretreatment with anti-CD44 and anti-b1
antibodies.
Previous work in our laboratory using an in vitro three-
dimensional model of the peritoneum has shown that tumour cells
rapidly adhere to human mesothelial cells prior to the initiation of
the invasive process (Jayne et al, 1999). We have also confirmed
that tumour adherence is shortly followed by destruction of the
mesothelial monolayer, in a process that involves mesothelial
retraction. However, mesothelial retraction is just one component
of a more complex cellular response that includes cell shrinkage,
nuclear fragmentation, and membrane-blebbing. On the basis of
these observations we hypothesised that mesothelial invasion
occurred as a result of tumour-induced mesothelial cell apoptosis.
If an apoptotic mechanism is indeed the driving force behind
mesothelial invasion, it begs the question as to which mediators of
apoptosis are involved. Tumour-induced apoptosis has been
implicated in other aspects of cancer biology, in particular as an
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sinstrument for evading immunological recognition (Griffith et al,
1995; Hahne et al, 1996). Central to many of these investigations
has been the death ligand/receptor system Fas Ligand (FasL)/Fas,
which has been shown to be involved in the apoptotic killing of
host immune cells (O’Connell et al, 1996). It seems reasonable
therefore to explore the possibility that a similar FasL/Fas
mechanism may be responsible for executing tumour-induced
mesothelial cell death.
The aims of the current study were therefore two-fold. Firstly, to
confirm that the changes in mesothelial morphology seen on co-
culture with tumour cells are in fact a result of mesothelial cell
apoptosis, and secondly, to explore the role of the FasL/Fas system
as a potential mediator of mesothelial apoptotic cell death.
MATERIALS AND METHODS
Cell culture and characterisation of human peritoneal
mesothelial cells
All cell culture equipment and reagents were purchased from
GibcoBRL (Life Technologies, Paisley, UK) unless otherwise stated.
Human peritoneal mesothelial cells were isolated from omental
biopsies obtained from resection specimens of patients undergoing
elective abdominal surgery (local ethical committee approved)
using a modification of a previously described method (Styliano
et al, 1990). Briefly, biopsies were washed in sterile 10% Hank’s
Balanced Salt Solution (HBSS) to remove excess blood contamina-
tion, and subjected to enzymatic degradation by incubation in
trypsin/HBSS (2.5mgml
 1)a t3 7 1C under continuous agitation for
20min. Liberated mesothelial cells were pelleted by centrifugation
(1000g for 10min, Mistral 2L, Measuring & Scientific Equipment
Ltd, Crawley, UK) and washed in Ham’s F-12 culture medium
supplemented with 10% Foetal Calf Serum (FCS). Mesothelial cells
were resuspended, counted, and plated into 25-cm
3 tissue culture
flasks coated with 0.1% gelatin (Sigma, Gillingham, UK) at 1 10
5
cellsml
 1. Cells were cultured to confluence (371C, 95% O2/5%
CO2 atmosphere) in Ham’s F12 medium supplemented with 10%
FCS, 5ml penicillin (25000IUml
 1), 5ml streptomycin
(5000mgml
 1), 50IU human soluble Insulin (Humulin S, Eli Lilly
& Company Ltd, Basingstoke, UK), bovine transferrin (5mgml
 1),
and hydrocortisone (0.4mgml
 1, Pharmacia & Upjohn Limited,
Milton Keynes, UK). This medium will subsequently be referred to
as Ham’s F12 complete medium. Media was changed every 3 days.
Mesothelial cultures were characterised by indirect immunofluor-
escent cytochemistry for cytoskeletal proteins cytokeratin 8, 18,
and vimentin, with contaminating endothelial and tumour cells
excluded by an absent expression of von Willibrand Factor and
BerEp4 antigens respectively. All experiments were performed on
cultures of passage 3 or less to avoid spurious results due to in
vitro phenotypic degeneration.
The human primary colonic cell line, SW480, was purchased
from the European Collection of Cell Cultures (ECCAC, Porton
Down, UK) and maintained in RPMI 1640 medium with L-
glutamine, supplemented with 10% FCS, 5ml penicillin
(25000IUml
 1) and 5ml streptomycin (5000mgml
 1).
Characterisation of tumour-induced mesothelial apoptosis
Mesothelial cells were seeded onto 1% gelatin coated glass
coverslips in six-well culture trays at 1 10
5 cellsml
 1 and grown
to confluence in Ham’s F-12 complete media at 371Ci na n
atmosphere of 95% O2/5% CO2. SW480 tumour cells were
passaged, their viability tested by trypan-blue dye exclusion, and
counted in an Improved Neubauer chamber. In total, 1 10
4
tumour cells/ml in RPMI-1640 supplemented media were seeded
onto the mesothelial monolayers and incubated at 371Ci na n
atmosphere of 95% O2/5% CO2. Changes in mesothelial morphol-
ogy in the co-cultures were recorded by serial time course
photomicroscopy.
Similar co-culture models were set up for dual-antigen
immunocytochemistry. Mesothelial apoptosis was detected in the
co-culture models by DNA fragmentation assay (Klenow-FragELt,
Calbiochem, Nottingham, UK), according to the manufacturer’s
instructions. SW480 tumour cells were identified by immunocy-
tochemical labelling with mouse anti-human BerEp4 antibody
(1:200 in PBSþ10% rabbit serum; Dako, Cambridgeshire, UK),
followed by a biotinylated rabbit anti-mouse secondary antibody
(1:500 in PBSþ10% rabbit serum, Dako), and visualised using the
alkaline phosphatase-streptavidin/Fast Redt system (Sigma,
Poole, UK). All slides were counterstained with Harris’s haema-
toxylin, and mounted in Aquamountt (BDH, Poole, UK). Images
were visualised with a Leitzt E1000 light microscope and recorded
with Luciat image-analysis software.
Co-culture model and quantification of mesothelial
apoptosis
Mesothelial cells were grown to confluence on 1% gelatin coated
glass coverslips in Hams’ F12 complete medium, and seeded with
SW480 at an effector:target ratio of 1:1. Cellular interactions were
terminated after 8h incubation by fixation with 3.5% paraformal-
dehyde in buffered saline at 41C for 15min, and mesothelial
apoptosis determined by DNA fragmentation assay using the In
situ Cell Death Detection Kit, Alkaline Phosphate (AP) (Boehringer
Mannheim Gmbh, Mannhein, Germany) as per manufacturers
instructions. Briefly, fixed apoptotic cells were permeabilised with
0.1% Triton X-100 in 0.1% sodium citrate for 2min at 41C, and
subjected to TdT-mediated dUTP nick end fluorescent labelling
(TUNEL). Incorporated fluorescein was detected using an anti-
fluorescein Fab antibody conjugated with alkaline phosphatase,
and visualised by incubation with Fast Red
TM for 10min at room
temperature. The mesothelial apoptotic index (AI) was calculated
by counting the number of apoptotic cells in 10 random high
power fields ( 200 magnification) using image-analysis software
as previously described (Lipponen et al, 1994). Apoptotic
mesothelial cells were readily differentiated from any contaminat-
ing apoptotic tumour cells by their position within the focal plane
of the microscope.
Positive controls included fixed permeabilised cells incubated
with DNAse 1 (Sigma) at 1mgml
 1 in 50mM Tris-HCl, pH 7.5,
1mgml
 1 BSA for 10min at room temperature. Omission of the
terminal transferase enzyme acted as a negative control. Mesothe-
lial monolayers and tumour cultures on their own were used as
sample controls. All experiments were repeated in triplicate.
To determine the potential involvement of soluble tumour
derived apoptotic factors, mesothelial monolayers were incubated
with different concentrations of preconditioned medium from
SW480 cultures.
Fas/FasL mRNA expression in SW480 and human
mesothelial cells
Total RNA was isolated from individual samples of SW480 and
human mesothelial cells using TRIzol
s Reagent (Life Technolo-
gies) as per manufacturer’s instructions, and 10ml of each reverse
transcribed using 120U of MMLV-reverse transcriptase (Promega,
Southampton, UK), 0.5mg of oligo d(t)18 primers, 1mmol of each
dNTP’s (Amersham Biosciences U.K. Limited, Chalfont St Giles,
UK), 20U of RNAsin (Promega), 5  reverse transcriptase reaction
buffer (250mmol Tris-HCl, (pH 8.3), 375mmol KCl, 15mmol
MgCl2 and 50mmol DTT, Promega) to a total volume of 20ml.
Reverse transcription was performed using a thermal program of
421C for 60min and 951C for 10min. PCR was performed by the
addition of 1ml of cDNA to a 20ml reaction mixture containing
10  Taq reaction buffer (500mM KCl, 100mM Tris-HCl (pH 9.0)
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sand 1% Triton
s X-100, Promega), 20pmol of each primer, 1U of
Taq Polymerase (Promega) and 0.2mM dNTPs. The mixture was
overlaid with 50ml of mineral oil to prevent evaporation. PCR was
initiated in a thermal cycler ((Biometra TRIO-Thermoblock,
Go ˜ttingem, Germany) and programmed for 35 cycles of 1min at
951C, 1min at 551C, 1min at 721C, and a final elongation step of
5min at 721C. Gene-specific primers were designed to span at least
one intron and included: human FasL, forward primer 50-
dCAGCTCTTCCACCTACAGAAGG-30 (bp 464–485) and reverse
primer 50-dAAGATTGAACACTGCCCCCAGG-30 (bp 889–910),
resulting in a product of 447bp length; human Fas, forward
primer 50-dCAAAGCCCATTTTTCTTCCA-30 (bp 499–518) and
reverse primer 50-dGACAAAGCCACCCCAAGTTA-30 (bp 755–
774), resulting in a product of 276bp length; and human GAPDH
as the house-keeper gene, forward primer 50-dGAGTCAACG-
GATTTGGTCGT-30 (bp 53–72) and reverse primer 50-
dGGTGCCATGGAATTTGCCAT-30 (bp 191–210), resulting in a
product of 158bp length. PCR products were resolved by
electrophoresis through 2% agarose gels and visualised by
ethidium bromide under UV fluorescence.
Human T-cells were isolated from healthy volunteers by
standard Ficoll density gradient centrifugation (Lymphoprept,
Nycomed Pharma AS, Drammensveien, Norway), stimulated with
1mgml
 1 of phorbol 12-myrisate 13-actetate (Sigma) for 48h, and
used as control samples for Fas and FasL expression in the PCR
reactions.
Determination of functional activity of FasL/Fas
To investigate the functional status of the Fas receptors,
mesothelial monolayers were incubated with either soluble FasL
recombinant protein (2.5ngml
 1) and enhancer (1mgml
 1)
(Alexis Corporation, Nottingham, UK) or agonistic anti-Fas
monoclonal antibody 2R2 (1mgml
 1) (Alexis Corporation) for 0,
2, 4, 6, 8, and 12h. Mesothelial apoptosis was quantified as above
using the In Situ Cell Death Detection Kit (Boehringer Mannheim).
To investigate the functional role of FasL/Fas interaction, SW480
FasL expression was blocked by preincubating SW480 cells with a
FasL inhibiting recombinant protein, which consisted of the
extracellular domain of human Fas fused to the Fc portion of
Human IgG1 (rhFas:Fc) (Alexis Corporation) at an optimum
concentration of 5mgml
 1 and enhancer protein 1mgml
 1 for
60min at 371C. The effect of tumour FasL blockade on mesothelial
apoptosis was quantified using the co-culture model as described
above.
Localisation of FasL/Fas expression by immunofluorescent
confocal microscopy
Investigation of SW480 and mesothelial FasL/Fas interaction was
performed on fixed co-cultures using a dual immunofluorescent
antigen detection technique. Samples were incubated with block-
ing solution (PBS supplemented with 10% goat and donkey serum)
for 60min, rinsed with PBS, and incubated with a primary rat
monoclonal anti-human FasL specific IgG antibody (Mike-1,
Alexis Corporation) at 1mgml
 1 and a primary mouse monoclonal
anti-human Fas specific IgG antibody (APO-1, Dako) at
0.15mgml
 1. Visualisation was performed using a TRITC con-
jugated goat anti-rat IgG secondary antibody (Chemicon Interna-
tional, Harrow, UK) at 0.5mgml
 1 and a FITC-conjugated donkey
anti-mouse IgG secondary antibody (Chemicon International) at
0.5mgml
 1 for FasL and Fas respectively. All samples were
mounted in Vectashield (Vecta Laboratories, CA, USA) and viewed
with a laser scanning confocal microscope (Lieca TCS-SP). Three-
dimensional image rotations were derived from confocal image
stocks using the confocal system software. Control samples were
exposed to blocking solution and secondary antibody alone.
Statistical analysis
Differences in apoptotic indices between the co-culture groups
were tested using the Mann–Whitney U-test, with a significance
level of Po0.05.
RESULTS
Tumour cells-induced mesothelial apoptosis
Phase-contrast microscopy of SW480-mesothelial co-cultures
showed that mesothelial cells adjacent to adherent tumour cells
underwent a change in cellular morphology with cytoplasmic
shrinkage, membrane blebbing, and nuclear fragmentation,
characteristic of apoptotic cell death (Figure 1). Time course
experiments using the co-cultures and TUNEL assay revealed that
mesothelial apoptosis occurred within hours of tumour seeding,
increased to a maximum by 8h, and returned to basal levels by
24h.
FasL/Fas mRNA expression in SW480 and human
mesothelial cells
RT–PCR analysis showed that human mesothelial cells constitu-
tively expressed Fas mRNA but not FasL mRNA. SW480 cells
expressed both FasL and Fas mRNA.
Mesothelial cells express functional Fas receptor
Pretreatment with either agonistic anti-Fas antibody or stimulating
crosslinked human FasL resulted in mesothelial cell death, which
was maximal at 4 and 6h respectively, as compared to untreated
controls (Figure 2).
Figure 1 Mesothelial-SW480 co-cultures. The tumour cells, T, induce
apoptosis in adjacent mesothelial cells, M. Mesothelial DNA fragmentation
is apparent as brown nuclear staining. Cell shrinkage and characteristic
membrane blebbing are apparent in (A) (Tumour cells unstained in this
experiment). (B–D), Dual staining of mesothelial-SW480 co-cultures.
Tumour cells (T) are identified by their position in the focal plane and by
their positive membrane staining (red) for BerEp4 epithelial antigen.
Adjacent mesothelial cells (M) show apoptotic changes with nuclear
fragmentation (brown). Bar, 2.5mm.
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sSW480 Tumour cells induce Fas-mediated apoptosis of
mesothelial cells
Co-culture of SW480 cells with mesothelial monolayers increased
the mean mesothelial AI by a factor of 700% compared to controls
(Figure 3, CC  vs M , Po0.001). Control cultures of mesothelial
monolayers alone showed a low basal rate of apoptosis. Negligible
tumour cell apoptosis was detected either in the co-cultures or in
SW480 cells cultured alone. Incubation of mesothelial monolayers
with SW480 preconditioned media of various concentrations and
for the same time points failed to significantly induce mesothelial
apoptosis.
Pretreatment of SW480 tumour cells with monoclonal anti-
human recombinant FasL reduced mesothelial apoptosis in co-
culture models by 290% compared to non-pretreated controls
(Figure 3, CC  vs CCþ, Po0.001). However, the mesothelial AI in
pretreated samples was still significantly greater than the basal
levels recorded in pure mesothelial cultures (Figure 3, CCþ vs
M , Po0.001). Treatment with anti-human FasL had no effect on
mesothelial monolayers or tumour cells cultured separately.
Localisation of Fas/FasL expression by immunofluorescent
confocal microscopy
Immunofluorescent staining revealed a homogeneous distribution
of cell membrane Fas expression in mesothelial cells (Figure 4A),
but no constitutive FasL expression. Mesothelial cell retraction was
seen in the vicinity of invading tumour cells, which expressed both
Fas and FasL protein (Figure 4B). In areas of tumour–mesothelial
adhesion, tumour FasL became polarised to areas of cell-to-cell
contact (Figure 4C and D), while mesothelial cell Fas expression
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Figure 2 Assessment of the functionality of human mesothelial Fas.
Mesothelial monolayers were incubated with an agonistic anti-Fas mAb or
stimulating crosslinked sFasL (dark columns). Controls were untreated
mesothelial monolayers (light columns). Mesothelial apoptosis was
detected using a TUNEL assay. Results are expressed as mean AI of
triplicate experiments7s.d. *Po0.05, Mann–Whitney U-test.
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Figure 3 Quantitative co-culture apoptosis assays. SW480 cells were
pretreated with a FasL inhibiting recombinant protein rhFas:Fc prior to
addition to mesothelial monolayers as co-cultures (CC). Monolayers (M)
and SW480 tumour cells (SW) were cultured alone as controls. 7
denotes pretreatment of cultures with recombinant protein. All co-culture
experiments were terminated at 8h. Mesothelial cell death is expressed as
mean AI of triplicate experiments7s.d. *Po0.05, Mann–Whitney U-test.
Figure 4 FasL/Fas interaction in tumour-mediated mesothelial apoptosis.
Dual confocal fluorescent microscopy of co-cultures with anti-FasL and
anti-Fas antibodies. FasL and Fas were visualised with a TRITC and FITC
secondary antibody respectively. Mesothelial cells demonstrate homo-
genous cell surface expression of Fas (A) and undergo cytoplasmic
retraction following tumour cell interaction (B). Tumour cell FasL is
polarised at areas of mesothelial contact (C, broken arrow). FasL is not
constitutively expressed by mesothelial cells but is induced by the presence
of adherent tumour cells (C, arrows). FasL channel only (D). M, mesothelial
cell. T, SW480 tumour cell. (A) Bar 20mm; (B) bar 20mm; (C) bar 5mm;
and (D) bar 10mm.
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sremained homogenous. Initially, the polarisation of tumour–FasL
was thought to be indicative of receptor–ligand interaction.
However, confocal studies using three-dimensional reconstruction
and detailed examination of individual confocal sections were
unable to confirm FasL/Fas co-localisation. Interestingly, mesothe-
lial expression of FasL, although not constitutively expressed, was
markedly induced in cells adherent with tumour cells (Figure 4C
and D). Incubation of pure mesothelial cultures with Fas-receptor
activators (agonistic anti-Fas mAb or crosslinked sFasL) failed to
upregulate mesothelial FasL mRNA expression on semiquantita-
tive PCR analysis (results not shown), indicating that increased
transcriptional activity was unlikely to account for the mesothelial
expression of FasL membrane protein seen in the co-culture
models.
DISCUSSION
We have demonstrated for the first time, using an in vitro model,
that a colorectal cancer cell line is capable of inducing human
mesothelial cell apoptosis. Although previous authors have
reported changes in mesothelial morphology, namely cytoplasmic
retraction, following intraperitoneal injection of tumour cells or
cytokines, the significance of these observations appears to have
gone unnoticed (Akedo et al, 1986). Using phase-contrast
microscopy and apoptosis detection assays we have shown that
the observed cellular retraction is but one component of a more
complex process that includes membrane-blebbing and nuclear
fragmentation, which are the hallmarks of apoptotic cell death. We
therefore propose that tumour-induced mesothelial apoptosis is an
important mechanism by which disseminated tumour cells breach
the mesothelium to gain access to the peritoneal connective tissue.
Previous authors have suggested that soluble tumour-derived
factors may be responsible for inducing mesothelial retraction.
However, these studies were performed in animal models using
high inoculations of tumour cells or unphysiological concentra-
tions of inflammatory cytokines. Contrary to these findings, in
human mesothelial cells we have demonstrated that tumour–
mesothelial adhesion is required for the induction of apoptosis,
which cannot be reproduced by the substitution of tumour-
conditioned media. This is supported by other in vitro work that
has implicated cell adhesion molecules, such as CD44 and the b1
integrins, in tumour-mesothelial invasion, (Schlaeppi et al, 1997;
Lessen et al, 1999; Strobel and Cannistra, 1999). The requirement
for cell–cell contact to initiate the invasive process supports the
role of cell membrane bound ligands, such as FasL, as the
mediators of mesothelial apoptosis. FasL, although primarily
expressed in cells of lymphoid lineage (Suda et al, 1993) and in
immune privileged sites (Bellgrau et al, 1995), has also been shown
to be expressed by a number of carcinomas, including colorectal
(Shiraki et al, 1997), hepatocellular (Strand et al, 1996) and lung
(Niehans et al, 1997). Furthermore, FasL is more frequently
expressed in colorectal liver metastases than in matched primary
carcinomas (Mann et al, 1998). The expression of FasL would
therefore appear to confer a selective advantage to metastasising
tumour cells.
Our RT–PCR and fluorescent immunocytochemistry data
demonstrates that SW480 carcinoma cells express FasL. This has
been previously documented in the SW480 cell line in addition to
other carcinoma cell lines (Shiraki et al, 1997; Mann et al, 1998;
O’Connell et al, 1998). Importantly, we have also shown that
human mesothelial cells constitutively express cell-surface Fas, a
previously undocumented finding, and that the mesothelial Fas
receptor is functionally active. Blocking of SW480 FasL activity
with a recombinant anti-FasL significantly reduced mesothelial
apoptosis in our co-culture model and supports the role of the Fas
death ligand/receptor system in mesothelial invasion. This
mechanism is analogous to that described by O’Connell et al
(1996) who showed that the colonic cell line, SW620, induces T-cell
apoptosis in a ‘counterattack’ mechanism of immune evasion via
engagement of tumour FasL and T-cell Fas. Similarly, immune cell
FasL has been implicated in the apoptotic cell death of hepatocytes
in viral hepatitis (Mita et al, 1994) and in the in vitro death of
hepatocytes by FasL expressing colon cancer cell lines (Yoong et al,
1999).
Further indirect evidence of FasL/Fas involvement in mesothe-
lial apoptosis is provided by our confocal microscopy studies.
Tumour FasL expression was localised to areas of tumour–
mesothelial adhesion suggesting its involvement in cell–cell
signalling. Unfortunately, we were unable to demonstrate tumour
FasL–mesothelial Fas co-localisation, which would have provided
strong proof of a FasL/Fas interaction at this site. Two possible
explanations exist for this. Firstly FasL/Fas interactions might
occur as rapid events, in low densities, making it difficult to
demonstrate at an isolated time point. Alternatively, individual
tumour cells from a heterogeneous cell line may utilise other death
ligands such as TRAIL. Certainly, FasL/Fas signalling is unlikely to
be the sole mechanism initiating mesothelial apoptosis, as
pretreatment of SW480 cells with recombinant anti-Fas only
partially reduced mesothelial apoptosis.
Restifo et al (2000) have disputed the FasL/Fas tumour ‘counter-
attack’ mechanism as being over-simplistic, while others (Zaks
et al, 1999) have demonstrated that in tumour–immune cell
interactions, lymphocytes initially recognise tumour cells via
MHC/T-cell receptor complexes and subsequently upregulate
their FasL expression. This in turn induces Fas-mediated
apoptosis in adjacent lymphocytes in a paracrine manner. We
have seen a similar upregulation of mesothelial FasL expression
in those cells in contact with adherent tumour cells by con-
focal microscopy. This increased FasL protein expression could
not be reproduced at the mRNA level by stimulation with
exogenous Fas receptor agonists. It is therefore possible that
mesothelial surface expression of FasL protein resulted from either
its rapid release from intracellular stores (Martinez-Lorenzo
et al, 1999) or by transcriptional upregulation induced by non-
Fas mediated signalling, for example by TRAIL or TNF-a (Herr
et al, 2000).
In summary, we believe tumour-induced mesothelial apoptosis
is an important mechanism in the process of peritoneal invasion.
By removing the defensive mesothelial barrier and allowing
exposure of adherent tumour cells to the underlying submesothe-
lial connective tissue, this mechanism represents an important first
step in the peritoneal metastatic cascade. The existence of
functional mesothelial Fas receptors, and the ability to inhibit
tumour-induced apoptosis by the use of blocking anti-FasL
proteins, suggests a role for these death ligands and receptors as
the mediators of mesothelial apoptosis. The intricacies of
mesothelial Fas signalling and, in particular, the significance of
upregulation of mesothelial FasL in the vicinity of adherent
tumour cells, remains an area of ongoing research. Further in vivo
investigations using animal models would be of value to
corroborate our findings for the role of FasL/Fas and to test its
efficacy as a possible therapeutic target. Of importance is the
discovery of a novel mechanism underlying peritoneal metastasis,
and with it the potential to identify and develop novel and more
specific therapeutic strategies to combat peritoneal carcinomatosis
of gastrointestinal origin.
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